Determination of Regulatory Review Period for Purposes of Patent Extension; Qelbree

Summary

The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for Qelbree, a human drug product, following the submission of patent extension applications to the U.S. Patent and Trademark Office (USPTO).